Paris-based biotech firm Phagos has raised €25 million in a Collection A funding spherical co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, with further participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital and Station F. The corporate, based in 2021 by Alexandros Pantalis and Dr Adèle James, develops bacteriophage-based therapies, a pure various to antibiotics, and holds the primary authorisation to market personalised phage-based veterinary therapies within the EU.
The brand new funding will help the deployment of veterinary therapies, additional improvement of Phagos’ patented AI know-how for phage discovery, and the corporate’s worldwide enlargement throughout Europe, Asia and the Americas.
Phagos’ method tackles one of the vital urgent challenges in international well being: bacterial resistance. Bacterial infections are presently the world’s second main reason for human mortality and a serious reason for animal deaths. Additionally they contribute to important meals waste and financial losses. Antimicrobial resistance already causes tens of millions of deaths yearly and will price the worldwide economic system as much as $100 trillion by 2050. In livestock, one in three antibiotics is now not efficient, a threefold enhance from 2000.
By combining microbiology and synthetic intelligence, Phagos’ platform can design ultra-precise and personalised phage-based therapies to fight bacterial illnesses. Its preliminary focus is on animal well being, focusing on infections equivalent to Salmonella and E. coli, with the long-term intention of extending its options to human well being.
Phagos’ regulatory approval marks a major milestone, making it the primary firm worldwide authorised to market personalised phage-based veterinary medication. The corporate has additionally filed a patent for its AI know-how, which may analyse the entire genomes of each phages and micro organism to foretell their interactions. This functionality permits Phagos to make phage remedy scalable, focused and efficient.
With this new funding, Phagos plans to increase its veterinary phage remedy options, strengthen its R&D efforts and scale the subsequent technology of its AI discovery know-how. The corporate is already collaborating with main trade gamers in subject deployments and intends to proceed its international enlargement. Its crew, presently composed of 90% scientific and technical professionals, may also develop to help market launches and product improvement.
“We’re satisfied that phage remedy can remodel the historical past of medication simply as antibiotics did within the final century. This funding offers us the means to speed up our mission and make this various accessible, quick, and efficient in opposition to the rise of bacterial resistance. Due to our regulatory breakthroughs and our patented platform combining microbiology and synthetic intelligence, we now have the chance to ascertain phage remedy as a world reference answer: for animal well being at the moment, and for human well being tomorrow,” mentioned Alexandros Pantalis and Adèle James, co-founders of Phagos.
“Antimicrobial resistance is a defining problem for international meals methods. With the unprecedented regulatory approval of its discovery platform, Phagos is main the way in which in deploying phage therapies as an actual, already actionable various to antibiotics. Our funding in Phagos underscores our sturdy dedication to deep tech improvements that drive a more healthy, extra sustainable, and resilient meals provide,” mentioned Anne-Valérie Bach, Managing Director of Capagro.
“Phagos’ pioneering platform supplies a high-efficiency various to antibiotics, providing a promising answer to a serious international well being disaster. This funding will assist the corporate change into a category-defining chief, reshaping how bacterial infections are handled with a transformative impression on each animal and human well being in a large international market,” added Rob Kniaz, Founder and Emeritus Accomplice of Hoxton Ventures.
